Enanta Pharmaceuticals, Inc. ENTA

Company Overview

Enanta Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of small molecule therapeutics for viral infections and immunology-related diseases. The company operates primarily in the biopharmaceutical industry, with research programs targeting respiratory syncytial virus (RSV), hepatitis B virus (HBV), COVID-19, and immune-mediated diseases. Enanta historically generated royalty revenue through its collaboration related to hepatitis C virus (HCV) therapies, particularly compounds licensed to AbbVie, while its current strategy emphasizes advancing internally developed clinical-stage pipeline assets.

The company’s principal business lines center on antiviral drug discovery, clinical development, and strategic licensing arrangements. Enanta serves global healthcare markets through partnerships, clinical collaborations, and commercialization-related agreements rather than direct large-scale product distribution. Its strategic positioning has historically been supported by expertise in structure-guided drug design and antiviral chemistry, particularly in virology-focused small molecule development. Founded in 1995 and headquartered in Massachusetts, Enanta evolved from an early-stage research organization into a publicly traded biotechnology company with multiple clinical and preclinical programs supported by royalty streams and research capabilities.